Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2018 1
2019 2
2020 1
2021 5
2022 1
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A; TuPro Consortium; Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, Levesque MP. Eichhoff OM, et al. Among authors: turko p. Cancer Res. 2023 Apr 4;83(7):1128-1146. doi: 10.1158/0008-5472.CAN-22-1826. Cancer Res. 2023. PMID: 36946761
Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.
Ferretti LP, Böhi F, Leslie Pedrioli DM, Cheng PF, Ferrari E, Baumgaertner P, Alvarado-Diaz A, Sella F, Cereghetti A, Turko P, Wright RH, De Bock K, Speiser DE, Ferrari R, Levesque MP, Hottiger MO. Ferretti LP, et al. Among authors: turko p. Cancer Res. 2023 Dec 1;83(23):3974-3988. doi: 10.1158/0008-5472.CAN-23-0485. Cancer Res. 2023. PMID: 37729428
MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production.
Langenbach M, Giesler S, Richtsfeld S, Costa-Pereira S, Rindlisbacher L, Wertheimer T, Braun LM, Andrieux G, Duquesne S, Pfeifer D, Woessner NM, Menssen HD, Taromi S, Duyster J, Börries M, Brummer T, Blazar BR, Minguet S, Turko P, Levesque MP, Becher B, Zeiser R. Langenbach M, et al. Among authors: turko p. Mol Cancer Res. 2023 Aug 1;21(8):849-864. doi: 10.1158/1541-7786.MCR-22-0898. Mol Cancer Res. 2023. PMID: 37071397 Free PMC article.
Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.
Ramelyte E, Tastanova A, Balázs Z, Ignatova D, Turko P, Menzel U, Guenova E, Beisel C, Krauthammer M, Levesque MP, Dummer R. Ramelyte E, et al. Among authors: turko p. Cancer Cell. 2021 Mar 8;39(3):394-406.e4. doi: 10.1016/j.ccell.2020.12.022. Epub 2021 Jan 21. Cancer Cell. 2021. PMID: 33482123 Free article.
SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth.
Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez Gomez JM, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan-Hersh E, Livneh I, Scortegagna M, Brown K, Larsson O, Topisirovic I, Wolfenson H, Herlyn M, Flaherty K, Dummer R, Ronai ZA. Lazar I, et al. Among authors: turko p. Mol Cancer Res. 2020 Oct;18(10):1560-1573. doi: 10.1158/1541-7786.MCR-20-0291. Epub 2020 Jun 22. Mol Cancer Res. 2020. PMID: 32571981 Free PMC article.
20 results